Table 1. Cases of sinonasal malignancy following cranial irradiation for brain tumor ( n = 14) .
Case # | Author, Year | Age (y) a | Gender | Primary cancer | Primary cancer treatment | Primary cancer radiation dose | Latency period b (y) | Secondary sinonasal cancer | Secondary cancer treatment | Outcome |
---|---|---|---|---|---|---|---|---|---|---|
1 | Goyal et al, 2015 | 17 | M | Glioblastoma multiforme | Radiotherapy, chemotherapy | 50.4 Gy, 28 fractions | 1.5 | Round cell carcinoma (undifferentiated) | Died after four cycles of chemotherapy | Rapid growth; died after 3 months |
2 | Ito et al, 2010 | 40 | F | Frontal glioma (low-grade) | Resection, radiotherapy, chemotherapy | 54 Gy, 27 fractions | 16 | Osteosarcoma | Died prior to planned resection | Rapid growth; died |
3 | Ito et al, 2010 | 46 | M | Bifrontal anaplastic oligoastrocytoma | Resection, radiotherapy, chemotherapy | 56 Gy, 28 fractions | 12 | Osteosarcoma | Died during radiotherapy treatment | Rapid growth; died |
4 | Park et al, 2008 | 39 | F | Pituitary adenoma (prolactinoma) | Resection, radiotherapy | 54 Gy, 30 fractions | 20 | Olfactory neuroblastoma | Resection, chemotherapy | Survived |
5 | Perez Garcia et al, 2011 | 43 | F | Bifrontal astrocytoma (low-grade) | Radiotherapy | 58 Gy, 5 fractions per week (holocranial 40 Gy, frontal 18 Gy) | 9 | Olfactory neuroblastoma | Resection, radiotherapy, chemotherapy | Recurrent twice; died after 13 months |
6 | Wallin et al, 2007 | 2.5 | M | Medulloblastoma and parietal meningioma | Radiotherapy (medulloblastoma), resection (parietal meningioma) | 45 Gy (23.4 Gy spine, 21.6 Gy posterior fossa) | 16.5 | Neuroendocrine carcinoma (poorly differentiated) | Resection | Survived |
7 | Kakkar et al, 2019 | 36 | F | Frontal diffuse astrocytoma | Resection, radiotherapy | 56 Gy, 28 fractions | 5.5 | Papillary adenocarcinoma | Resection | No disease evident at 8 months |
8 | Patel et al, 2017 | 54 | M | Anaplastic oligoastrocytoma | Resection, radiotherapy, chemotherapy | NS | 16 | Carcinosarcoma | Resection, Cesium-131 brachytherapy | No disease evident at 9 months |
9 | Nery et al, 2022 | 48 | M | Pituitary macroadenoma | Resection, radiotherapy | NS | 12 | Mucoepidermoid carcinoma | Resection, radiotherapy, chemotherapy | Survived |
10 | Sahoo et al, 2022 | 12 | M | Medulloblastoma | Resection, radiotherapy, chemotherapy | 56 Gy, 30 fractions | 2 | Olfactory neuroblastoma | Resection | Died after 8 months |
11 | Christopherson et al, 2014 | 7.1 c | NS | Medulloblastoma | Resection, radiotherapy, chemotherapy | 54 Gy (craniospinal 28.8 Gy) d | 6.4 | Rhabdomyosarcoma | Radiotherapy, chemotherapy | Treatment successful; last follow-up unknown |
12 | Packer et al, 2013 | 6.8 c | NS | Medulloblastoma | Resection, radiotherapy, chemotherapy | 55.8 Gy (23.4 Gy craniospinal, 32.4 Gy posterior fossa) | 4.8 | Spindle cell carcinoma | Unknown | Survived at least 1.67 years |
13 | Delank and Ballantyne, 1993 | 68 | M | Pituitary adenoma (prolactinoma) | Resection, radiotherapy, chemotherapy | 1.8 Gy | 6.5 | Malignant melanoma | Resection, radiotherapy | Died after 1.5 years |
14 | Delank and Ballantyne, 1993 | 65 | M | Pituitary adenoma | Resection, radiotherapy | 3.0 Gy | 10 | Olfactory neuroblastoma | Radiotherapy, chemotherapy | Died after 9 months |
Abbreviations: F, female; Gy, gray (unit); M, male; NS, not specified.
Age at diagnosis of brain tumor.
Time between irradiation of the brain tumor and diagnosis of the secondary sinonasal malignancy.
Median age of study participants; participant-specific ages not specified.
Median dose administered to study participants; participant-specific doses not specified.